Summary
27.08
-0.30
(-1.10%)
07/10/2026
Legend Biotech Corporation (LEGN)Key Facts
Performance
Historical returns1D
-1.10%
1W
-3.42%
1M
-22.32%
3M
49.12%
6M
14.26%
1Y
-31.81%
5Y
-31.98%
Snapshot
Key statisticsClose
27.08
Change
-0.30
Change %
-1.10%
Open
27.45
Day Range
26.52 – 27.53
Volume
1,343,006
Avg Vol (20d)
2,344,476
Rel Vol
0.57x
52W Range
16.24 - 45.30
vs 52W High
-40.22%
vs 52W Low
66.75%
Gap
-0.68
Market Cap
USD 2.91B
Beta
0.07
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Financial SnapshotFY 2025
Full financialsRevenue
USD 1.03B
+64.0% YoY
Net Income
-USD 297.58M
+88.2% YoY
EPS
-1.60
-17.5% YoY
Gross Margin
60.3%
Operating Margin
-13.3%
Net Margin
-28.9%
EBITDA
-USD 232.30M
Free Cash Flow
-USD 168.04M
-16.3% margin
ROE
-29.7%
ROA
-17.2%
Debt / Equity
0.41x
net debt -USD 488.20M
Cash & Equiv.
USD 901.90M
Fundamental Ratings
MainC-
RecommendedStrong Sell
DCFStrong Sell
ROEStrong Sell
ROAStrong Sell
Debt/EquitySell
P/EStrong Sell
P/BSell
Latest Earnings
- LEGN reported last earnings on 2026-05-12.
- EPS of $-0.15 vs $-0.02 estimated — surprise $-0.13.
- Revenue of $305M vs $307M estimated — surprise $-1M.
News
All newsLegend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 1% on Thursday.
Legend Biotech Corporation Announces Pricing of Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each...
Legend Biotech Corporation Announces Proposed Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of American Depositary Shares...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion No dose-limiting toxicities, serious adverse...
Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
Legend Biotech (LEGN) remains a buy as Carvykti's earlier-line use drives superior efficacy, safety, and manufacturing success, signaling a structural shift in multiple myeloma therapy. Recent CARTITUDE-4 data show earlier Carvykti use extends progression-free and overall survival, with...
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell...
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed...
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use
Legend Biotech NASDAQ: LEGN used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson.
Legend Biotech Announces Presentations at ASCO 2026
SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including a rapid oral...
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Legend Biotech Corp (NASDAQ:LEGN) reported downbeat results for the first quarter on Tuesday.
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Legend Biotech Q1 Earnings Call Highlights
Legend Biotech NASDAQ: LEGN reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded.
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million CARVYKTI ® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and Australia Advanced early-stage cell...
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguished scientific advisors who will provide strategic input as Legend advances its pipeline and future...
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results.